| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Pulsenmore Ltd. Ordinary Shares$3.53
-0.12 (-3.29%)
F 10Pipeline Score Tools & Services · Clinical
Market Cap
23.35 M
EPS
-0.78
P/E Ratio
-4.62 $
Value Trade
34.93 K
%
Week
%
1 Month
%
3 Month
%
6 Month
%
5 Year
%
All Time
Cash Data
Cash Position
-
Monthly Burn
-
Runway
-
Overview
Volume
19.90 K
52 Week Range
3.00 - 10.28
% held by Insiders
40.65 %
% held by Institutions
7.72 %
Enterprise Value
2.10 M
Total Shares
6.50 M
Short %
8.35 %
Float Shares
5.86 M
Company Description
locked
Upcoming Catalyst
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
— | Example Drug | Phase 3 data readout | Phase 3 | — | – | 0% | 0% |
Drug Pipeline Intelligence
F10
Pipeline Score -
Pipeline ValueValuation Signal
0
Drugs Scored—
rNPV / MCap Top 8%
Micro Cap (rank 850 of 923)
Percentile RankPulsenmore Ltd. Ordinary Shares has significant pipeline risk (10/100).
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in PLSM
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
PLSM Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
-PLSM
Jul 13, 2026▼ -6.2%on this news
Pulsenmore Selected for Israel Innovation Authority and Ministry of Health Program to Lead an $1 Million AI Development Project
Pulsenmore Ltd. has been chosen for Israel's Healthcare AI Regulatory Sandbox Program, receiving funding to develop AI applications for its home ultrasound platform. This initiative aims to improve clinical workflow and scalability, allowing for faster and more efficient patient care. Collaborating with Beilinson Hospital, Pulsenmore seeks to validate its AI solutions, leveraging a unique dataset from over 250,000 home ultrasound scans.
Read more →-PLSM
Jun 25, 2026▼ -10.5%on this news
Pulsenmore Announces Pricing of $7.5 Million Private Placement with a Single Healthcare Focused Institutional Investor
Pulsenmore Ltd. has announced a $7.5 million private placement with a healthcare-focused institutional investor. The agreement involves the sale of 1,562,500 ordinary shares and warrants at a price of $4.80 per share. The funds will be used for marketing, commercialization, and general corporate purposes, supporting the company's growth strategy in the U.S. market.
Read more →-PLSM
Jun 24, 2026▲ +93.3%on this newsshared move
Pulsenmore Announces Strategic Partnership with Ouma Health to Expand Access to Remote Prenatal Care Across the United States
Pulsenmore Ltd. has partnered with Ouma Health to integrate its FDA-authorized home ultrasound technology into Ouma's virtual maternity care model. This collaboration aims to enhance access to remote prenatal care across the United States, creating a scalable solution for the adoption of home ultrasound in prenatal care. The partnership signifies a step forward in improving maternal health services.
Read more →-PLSM
Mar 30, 2026Pulsenmore Announces Full Year 2025 Financial Results and Webcast Management to Host Conference Call and Webcast today at 8:30am ET to Discuss Results and Provide Business Update
Pulsenmore Ltd. announced its financial results for the year ending December 31, 2025, highlighting a 374% increase in revenue, largely due to a one-time payment from a settlement with GE Precision Healthcare. The company's net loss improved to $5 million, reflecting ongoing operational investments. Critical regulatory milestones were achieved, including FDA clearance for a remote prenatal ultrasound device and CE Certification for its early-screening product in Europe. The company is hosting a webcast to discuss these results and future business strategies.
Read more →-PLSM
Feb 9, 2026Pulsenmore Builds U.S. Momentum with Another Commercial Engagement Following FDA Clearance
Pulsenmore Ltd. has entered a new commercial agreement with TLC Perinatal PA, a maternal-fetal medicine and women's ultrasound practice in Maryland, following its FDA clearance. This partnership is part of Pulsenmore's strategy to expand its U.S. footprint by integrating home ultrasound services into existing clinical workflows. The agreement aims to provide a physician-directed hybrid care model combining telehealth and in-clinic visits, which aligns with modern prenatal care protocols. The collaboration signifies growing interest among healthcare practices to adopt innovative, patient-centric technologies in managing pregnancy care.
Read more →-PLSM
Feb 2, 2026Pulsenmore Announces First Commercial Engagement with a Leading U.S.-Based Medical Center
Pulsenmore Ltd. has announced its first commercial engagement with the Center for Fetal Medicine & Women's Ultrasound in Los Angeles, following FDA approval for its home pregnancy ultrasound product. This partnership allows for the deployment of remote pregnancy monitoring services, aimed at improving access to obstetric healthcare for expectant mothers. The CEO of Pulsenmore highlighted this as a significant milestone in their strategic plans in the U.S. market, where they see substantial potential for expansion.
Read more →-PLSM
Jan 26, 2026Pulsenmore and Clalit Health Services Launch First At-Home Follicular Monitoring Service for IVF and Fertility Preservation Commercial agreement potentially valued at approximately $4.5 million over five years following
Pulsenmore Ltd. has entered a strategic partnership with Clalit Health Services to introduce an at-home ultrasound solution for fertility monitoring. This service, named Pulsenmore FC, will enable patients to conduct follicular scans from the comfort of their homes, supported by a mobile app and real-time guidance from specialists. The commercial agreement, potentially valued at $4.5 million over five years, follows a successful pilot program. This initiative aims to enhance patient care while minimizing the frequency of in-clinic visits, aligning with a new model of healthcare delivery.
Read more →-PLSM
Jan 21, 2026Pulsenmore To Commence Trading on Nasdaq as It Expands FDA-authorized Home Prenatal Ultrasound Devices in the U.S. Ramat Gan, Israel
Pulsenmore Ltd. has announced that its shares will commence trading on the Nasdaq starting today, a significant move as the company expands its FDA-authorized home prenatal ultrasound devices in the U.S. This milestone reflects Pulsenmore's strategy to enhance visibility and liquidity in the market while potentially increasing shareholder value. Through its innovative technology, the company aims to improve maternal health by facilitating remote prenatal monitoring. The listing is seen as a transformative step in Pulsenmore's operations and growth strategy in the healthcare sector.
Read more →Competitive Position
How PLSM ranks across every disease it competes inCompetitive Position is a premium feature
See how PLSM ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial